Eighty Years in Five Acts
The modern history of psychedelic science is short enough to hold in one hand and strange enough to fill a library: two golden ages separated by a forty-year blackout, a discovery made on a bicycle, a CIA program nobody authorized, a sacred mushroom brought down a mountain by a curandera, and a renaissance that rebuilt, in fifteen years, what politics erased in one. Knowing the timeline matters beyond trivia, because the field's current questions, its regulatory posture, its cultural tensions, and its unfinished business all carry timestamps from this history. This post is the arc in five acts.
Act One: Discovery (1943 to 1953)
Sandoz Laboratories in Basel, April 1943: Albert Hofmann synthesizes LSD-25 for the fifth time, absorbs a trace through his skin, and experiences history's first acid trip on his bicycle ride home. The compound he calls his "problem child" is released to researchers in 1947 as Delysid, and psychiatry's first golden age begins within the decade. The parallel discovery track runs through the Americas: R. Gordon Wasson's 1955 visit to María Sabina in Huautla de Jiménez, guided by the Mazatec curandera to the teonanácatl, brings psilocybin to Western science; Hofmann isolates and names the compound in 1958. Mescaline's chemistry had been characterized decades earlier, but the 1950s complete the toolkit: LSD, psilocybin, and mescaline all enter legitimate research within a fifteen-year window.
Act Two: The Golden Age (1953 to 1966)
The 1950s produced a research literature of remarkable breadth, given how brief the window was. Over a thousand clinical papers on LSD alone explored alcoholism (with results that, in modern re-analysis, look better than their era's methodology could prove), anxiety in terminal patients, depression, and the model psychosis question, whether the LSD experience could illuminate schizophrenia. Humphry Osmond coins the word "psychedelic" in a 1956 letter to Aldous Huxley. The Aldous Huxley of Brave New World and The Doors of Perception becomes the movement's literary ambassador, and the compounds acquire a cultural charisma that the research alone would never have generated. The dark seed arrives in the same years: MKULTRA, the CIA's covert program dosing unwitting subjects with LSD across eighty institutions, runs from 1953 until exposure in the 1970s. Its revelation would later poison the well of public trust around anything touching these compounds, a legacy the renaissance still metabolizes.
Act Three: The Blackout (1966 to 1990)
The cultural turn is fast and total. Timothy Leary's public evangelism, the Harvard Psilocybin Project's collapse into scandal, and the compounds' adoption as counterculture sacraments make them political symbols rather than research tools. By 1966, California has criminalized LSD; by 1970, the Controlled Substances Act schedules the classical psychedelics alongside heroin; by 1971, the UN Convention on Psychotropic Substances locks the schedule into international law. The research apparatus evaporates: grant money disappears, institutional review boards close the door, and a thousand-article literature goes dormant. A thin underground persists through the decades, the MAPS foundation founded in 1986 by Rick Doblin being its most consequential institution, keeping the therapeutic hypothesis alive on shoestring funding through the entire winter. A quiet countercurrent also runs through the period: the Santo Daime and UDV churches' legal battles in Brazil and the United States preserve the entheogenic and religious-freedom arguments that later frameworks draw upon.
Act Four: The Thaw (1990 to 2016)
The thaw begins at the margins and moves inward. Brazilian courts formalize ayahuasca religious use in 1987. The UDV wins its U.S. Supreme Court case in 2006, establishing religious freedom as a live legal theory for sacramental plants. And in 1999, the FDA quietly approves the first modern psychedelic protocol in decades: a Hopkins study of psilocybin and mystical experience in healthy volunteers, run by Roland Griffiths, a drug-abuse researcher with no prior psychedelic involvement, whose 2006 publication in Psychopharmacology becomes the renaissance's founding document. The trial's careful design, institutional pedigree, and striking results reopen the scientific door. The following decade builds methodically: MAPS' MDMA-for-PTSD program advances through the FDA's phased pathway; Imperial College's Robin Carhart-Harris begins the imaging work that gives the field its mechanistic story; the first modern end-of-life trials report their results.
Act Five: The Renaissance (2016 to Now)
The renaissance's milestones arrive in accelerating sequence. Breakthrough Therapy designations from the FDA for psilocybin (2018, depression) and MDMA (2017, PTSD) signal regulatory engagement. COMPASS Pathways' public listing in 2020 brings institutional capital and, with it, the field's patent wars and commercial tensions. Oregon's Measure 109 (2020) and Colorado's Proposition 122 (2022) create the first licensed adult-access frameworks anywhere, running in parallel with, and partially in tension with, the medical pathway. Australia's 2023 authorized-prescriber scheme leaps past the FDA to national-level MDMA and psilocybin authorization. The setback arrives on schedule: the FDA's 2024 MDMA rejection forces the field's methodological maturation, and the research rebuilds around more rigorous designs. As of 2026, the landscape holds all of it at once: clinical trials, licensed services, decriminalized cities, retreat industries, and a Schedule I federal baseline, in productive contradiction.
What the Timeline Teaches
Three lessons deserve the last word. First, the blackout was the anomaly, not the research: human cultures and then Western science spent decades in productive relationship with these compounds before a single political convulsion erased the whole structure, and the renaissance's speed suggests the interruption, not the interest, was the fragile thing. Second, the field's recurring vulnerabilities repeat on schedule: hype outrunning evidence, commercial interests outrunning ethics, and cultural charisma outrunning method. The 2024 MDMA decision was, in this light, the system working as designed, slowly, against the enthusiasm that the timeline's own golden ages generated. Third, the traditions never left: the Mazatec lineages, the Santo Daime churches, the ayahuasca peoples kept the knowledge through the blackout, and the modern field's legitimacy increasingly depends on how it honors the continuity. The timeline is not a museum. It is a map of the forces, political, scientific, commercial, and spiritual, that are still contesting the compounds' future, and the next act is being written by whoever reads it carefully.
